about
A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirementsImaging Modalities to Identity Inflammation in an Atherosclerotic Plaque.25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future PerspectivesMR angiography of collateral arteries in a hind limb ischemia model: comparison between blood pool agent Gadomer and small contrast agent Gd-DTPADesign of ProCAs (protein-based Gd(3+) MRI contrast agents) with high dose efficiency and capability for molecular imaging of cancer biomarkersInteractions of nanomaterials and biological systems: Implications to personalized nanomedicineNew dual mode gadolinium nanoparticle contrast agent for magnetic resonance imagingProgress in atherosclerotic plaque imaging.Positive contrast high-resolution 3D-cine imaging of the cardiovascular system in small animals using a UTE sequence and iron nanoparticles at 4.7, 7 and 9.4 T.The art of attraction: applications of multifunctional magnetic nanomaterials for malignant glioma.Gd Complexes of DO3A-(Biphenyl-2,2'-bisamides) Conjugates as MRI Blood-Pool Contrast Agents.T₁-weighted ultrashort echo time method for positive contrast imaging of magnetic nanoparticles and cancer cells bound with the targeted nanoparticles.Enabling individualized therapy through nanotechnologyRapid MR venography in children using a blood pool contrast agent and multi-station fat-water-separated volumetric imaging.Detection of vascularity in wrist tenosynovitis: power doppler ultrasound compared with contrast-enhanced grey-scale ultrasound.In vivo quantification of contrast agent concentration using the induced magnetic field for time-resolved arterial input function measurement with MRI.Gadofosveset-based biomarker of tissue albumin concentration: Technical validation in vitro and feasibility in vivo.Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children.Safety and technique of ferumoxytol administration for MRI.Overcoming the low relaxivity of gadofosveset at high field with spin locking.Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?MR Vascular Fingerprinting in Stroke and Brain Tumors Models.Diagnostic accuracy of contrast-enhanced MR angiography in severe carotid stenosis: meta-analysis with metaregression of different techniques.MR angiographic follow-up of intracranial aneurysms treated with detachable coils: evaluation of a blood-pool contrast medium.Contrast-enhanced peripheral MRA: technique and contrast agents.Therapeutic nanoparticles in clinics and under clinical evaluation.Emerging applications for ferumoxytol as a contrast agent in MRI.Extracardiac applications of MR blood pool contrast agent in children.Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol.High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort.Use of blood pool agents with steady-state MRI to assess the vascular system.A comparison between gadofosveset trisodium and gadobenate dimeglumine for steady state MRA of the thoracic vasculature.Characterization of carotid artery plaques with USPIO-enhanced MRI: assessment of inflammation and vascularity as in vivo imaging biomarkers for plaque vulnerability.4D flow image quality with blood pool contrast: a comparison of gadofosveset trisodium and ferumoxytol.Ferumoxytol-enhanced magnetic resonance angiography for the assessment of potential kidney transplant recipients.Encapsulation of superparamagnetic nanoparticles into red blood cells as new carriers of MRI contrast agents.A multiple gadolinium complex decorated fullerene as a highly sensitive T(1) contrast agent.
P2860
Q26744352-2C48DAD4-590B-4404-839A-97F3A66F1618Q26769824-84167459-3880-403F-A3E9-32FC2C3D3F6EQ26774810-8D57476E-4584-4FCF-9F36-49B0CB54A2DEQ27437647-97F98400-809A-4D27-8E0D-B9589339A082Q28235682-6851C9D4-BAE7-4503-8085-35487A19BE96Q28391849-7EEBE627-6D96-405C-AD5E-F50D12A0B04DQ28471645-F4B5DABD-C8A2-41EE-96F4-73C8ADC6274DQ30464390-A9E3CB73-2B4B-4054-9BE9-6D55BDBBC44AQ30656936-9E40919F-BA95-4EB0-B0B3-2E2A5A1F20C1Q30809060-B9BC6791-17B0-4F70-8DFD-3CFE9A9136D4Q30829168-28886358-1B20-4556-A43B-B364C7AEFB1AQ33779313-C35EC1E5-5ABD-4832-9CA7-5C090EF37C4EQ33917755-FA0E9FF1-296A-4EF5-8A7E-903F05E7CFE9Q34046910-E7C839EF-794E-4FB2-B37C-8C191F68DA09Q34613951-0ADCD994-6E76-4C4D-8377-A223EEB2B507Q34931446-EE641B84-5880-4268-84AA-EE119A8A50C9Q34974971-5E652077-3836-4148-9806-3092741A3247Q35656127-C58CD7DE-4D54-4FC3-BD45-B0F6AD5FA2D6Q36862859-5D1885C9-761F-4534-8766-279F9A1519ADQ36882304-E396EED0-662F-4057-8B28-49E5D3D782CDQ37098753-26B8982B-70F2-460F-94EC-98E5B9847109Q37435184-7DCF4A88-3B47-4FD4-B90F-E7982DF8DE73Q37462355-BA21E2ED-BA24-4691-9D28-8A0AD46D00E4Q37480283-7CE27008-E37B-4B2C-A669-FD20AB7DA082Q38030503-8E8FC6C6-ED49-4AC0-8D0A-3D1BD7A3242CQ38087986-C4586FB1-587F-449D-8AFB-514AFADAD4BFQ38224182-AE8688B7-ED91-443B-84C8-6FC200A3C385Q38269422-4D67948E-FF92-4E9E-AD56-CEA2C693A6DDQ38802402-9FAD3E77-C255-43EC-9FFE-3BC923C017E1Q39130795-0972C359-3DE2-4FD2-A138-6AEED2E5F015Q39250421-5F524B74-01DF-453F-B584-87C45559F345Q41891580-9EF0D368-03C2-4B30-AF9E-B1DAFA5BAA5BQ45739358-A774235D-D2CA-42CB-8C67-80DD2E01144BQ46655327-5EC42F6C-9AA5-4F49-9EC5-98F7C72E1801Q47199588-BBD85768-E6FC-4052-8C74-24ADE8F958CCQ50543296-CB839A4D-D482-4BD0-8FD9-872E441D6FAEQ51008833-6A66CFCA-B03B-4C67-8E2F-85A9058A54FD
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
MR angiography with blood pool contrast agents.
@en
type
label
MR angiography with blood pool contrast agents.
@en
prefLabel
MR angiography with blood pool contrast agents.
@en
P2860
P1433
P1476
MR angiography with blood pool contrast agents.
@en
P2093
Deniz Bilecen
Peter Reimer
P2860
P2888
P304
P356
10.1007/S00330-007-0712-0
P407
P577
2007-07-17T00:00:00Z